{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:40:06Z","timestamp":1721277606105},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00393-019-0646-3","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T17:32:11Z","timestamp":1558027931000},"page":"587-598","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neue Substanzen zur Therapie der juvenilen idiopathischen Arthritis","New drugs for treatment of juvenile idiopathic arthritis"],"prefix":"10.1007","volume":"78","author":[{"given":"Gerd","family":"Horneff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"issue":"11","key":"646_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA et\u00a0al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N\u00a0Engl J Med 342(11):763\u2013769","journal-title":"N Engl J Med"},{"issue":"8","key":"646_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S et\u00a0al (2008) Pediatric rheumatology collaborative study group; pediatric rheumatology international trials Organisation. Adalimumab with or without Methotrexate in juvenile rheumatoid arthritis. N\u00a0Engl J Med 359(8):810\u2013820","journal-title":"N Engl J Med"},{"issue":"1","key":"646_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2017","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-P\u00e9rez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Vel\u00e1zquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell DJ, Martini A, Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) (2017) Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a\u00a0multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis 77(1):21\u201329. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210456","journal-title":"Ann Rheum Dis"},{"key":"646_CR4","unstructured":"Brunner HI, Ruperto N, Keltsev V, Alexeeva E, Abud-Mendoza C, Schmeling H, Maldonado-Vel\u00e1zquez MDR, Rubio-P\u00e9rez N, Stanislav M, Chasnyk V, Brown D, Henrickson M, Kingsbury D, Rabinovich CE, Zeft A, Silverman E, Wang M, Charlton P, Lledo-Garcia R, Shaughnessy L, Lovell DJ, Martini A (2016) A multi-center, open-label study to assess the Pharmacokinetics, efficacy and safety of Certolizumab pegol in children and adolescents with moderately to severely active Polyarticular-course juvenile idiopathic arthritis: week 24 results [abstract]. Arthritis Rheumatol 68(suppl 10):"},{"issue":"17","key":"646_CR5","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW, SYCAMORE Study Group. (2017) Adalimumab plus methotrexate for Uveitis in juvenile idiopathic arthritis. N\u00a0Engl J Med 376(17):1637\u20131164","journal-title":"N Engl J Med"},{"issue":"10089","key":"646_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","volume":"390","author":"K Papp","year":"2017","unstructured":"Papp K, Tha\u00e7i D, Marcoux D, Weibel L, Philipp S, Ghislain P\u2011D et al (2017) Efficacy and safety of adalimumab every other week versus methotrexate in pediatric patients with severe chronic plaque psoriasis: A randomized, double-blind phase 3 study. Lancet 390(10089):40\u201349","journal-title":"Lancet"},{"key":"646_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpeds.2018.05.042","volume":"201","author":"G Horneff","year":"2018","unstructured":"Horneff G, Seyger MMB, Arikan D et al (2018) Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn\u2019s disease. J\u00a0Pediatr 201:166\u2013175.e3","journal-title":"J Pediatr"},{"issue":"1","key":"646_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13075-016-1109-8","volume":"18","author":"T Beukelman","year":"2016","unstructured":"Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR (2016) The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther 18(1):210","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"646_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acr.22961","volume":"69","author":"I Becker","year":"2017","unstructured":"Becker I, Horneff G (2017) Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry. Arthritis Care Res (Hoboken) 69(4):552\u2013556","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"646_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","volume":"14","author":"G Horneff","year":"2015","unstructured":"Horneff G (2015) Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 14:1111\u20131126","journal-title":"Expert Opin Drug Saf"},{"key":"646_CR11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.34348","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:1263\u20131271","journal-title":"Arthritis Rheum"},{"issue":"1","key":"646_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/rheumatology\/keq361","volume":"50","author":"G Horneff","year":"2011","unstructured":"Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology 50(1):230\u2013236","journal-title":"Rheumatology"},{"issue":"6","key":"646_CR13","first-page":"1113","volume":"34","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K (2016) A Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clin Exp Rheumatol 34(6):1113\u20131120","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"646_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/art.1780340112","volume":"34","author":"RJ Smith","year":"1991","unstructured":"Smith RJ, Chin JE, Sam LM, Justen JM (1991) Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 34(1):78\u201383","journal-title":"Arthritis Rheum"},{"issue":"7","key":"646_CR15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA (2012) Juvenile idiopathic arthritis disease-specific research committee of childhood arthritis rheumatology and research alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 64(7):1001\u20131010","journal-title":"Arthritis Care. Res."},{"issue":"1","key":"646_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N, Hufnagel M, Jansson AF, Hedrich C, Winowski H, Berger T, Foeldvari I, Ganser G, Hospach A, Huppertz HI, M\u00f6nkem\u00f6ller K, Neudorf U, Wei\u00dfbarth-Riedel E, Wittkowski H, Horneff G, Foell D (2018) PRO-KIND SJIA project collaborators. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online\u00a0J 16(1):7","journal-title":"Pediatr Rheumatol Online J"},{"issue":"25","key":"646_CR17","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO, PRCSG (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N\u00a0Engl J Med 367(25):2396\u20132406","journal-title":"N Engl J Med"},{"issue":"12","key":"646_CR18","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","volume":"77","author":"N Ruperto","year":"2018","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ, Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group (PRCSG) (2018) Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5\u2011year long-term extension of the phase III pivotal trials. Ann Rheum Dis 77(12):1710\u20131719","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"646_CR19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, Wulffraat NM (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a\u00a0prospective cohort study. Arthritis Rheumatol 66(4):1034\u20131043","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl","key":"646_CR20","first-page":"A482","volume":"77","author":"G Horneff","year":"2018","unstructured":"Horneff G, Schulz AC, Klein A, Eising K (2018) Anakinra for first line steroid free treatment in systemic onset juvenile arthritis. EULAR18-2161. Ann Rheum Dis 77(Suppl):A482","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"646_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/03009742.2017.1288827","volume":"46","author":"G Horneff","year":"2017","unstructured":"Horneff G, Peitz J, Kekow J, Foell D (2017) Canakinumab for first line steroid-free treatment in a\u00a0child with systemic-onset juvenile idiopathic arthritis. Scand J Rheumatol 46(6):500\u2013501","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"646_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-017-0157-1","volume":"15","author":"Y Kimura","year":"2017","unstructured":"Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, Graham TB, Ibarra M, Ilowite N, Klein-Gitelman M, Onel K, Prahalad S, Punaro M, Ringold S, Toib D, Van Mater H, Weiss JE, Weiss PF, Schanberg LE, Registry Investigators CARRA (2017) Pilot study comparing the childhood arthritis & rheumatology research alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans. Pediatr Rheumatol Online\u00a0J 15(1):23","journal-title":"Pediatr Rheumatol Online J"},{"issue":"25","key":"646_CR23","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, PRINTO, PRCSG (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N\u00a0Engl J Med 367(25):2385\u20132395","journal-title":"N Engl J Med"},{"key":"646_CR24","doi-asserted-by":"publisher","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-P\u00e9rez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, G\u00e1mir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) (2014) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a\u00a0phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110\u20131117. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205351","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"646_CR25","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ et\u00a0al (2015) Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a\u00a0phase III study. Arthritis Rheumatol 67:1424\u20131437","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"646_CR26","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 76(5):840\u2013847. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210310","journal-title":"Ann Rheum Dis"},{"issue":"9999","key":"646_CR27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landew\u00e9 R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S, FUTURE 2 Study Group (2015) Secukinumab, a\u00a0human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a\u00a0randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386(9999):1137\u20131146","journal-title":"Lancet"},{"issue":"4","key":"646_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group, FIXTURE Study Group (2014) Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials. N\u00a0Engl J Med 371(4):326\u2013338","journal-title":"N Engl J Med"},{"issue":"4","key":"646_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group (2016) Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N\u00a0Engl J Med 375(4):345\u2013356","journal-title":"N Engl J Med"},{"issue":"2","key":"646_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Tha\u00e7i D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A (2016) A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 175(2):273\u2013286","journal-title":"Br J Dermatol"},{"issue":"9625","key":"646_CR31","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators (2008) Efficacy and safety of ustekinumab, a\u00a0human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a\u00a0randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675\u20131684","journal-title":"Lancet"},{"issue":"9664","key":"646_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","volume":"373","author":"A Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A (2009) Ustekinumab, a\u00a0human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664):633\u2013640. https:\/\/doi.org\/10.1016\/S0140-6736(09)60140-9 (Erratum in: Lancet. 2009 Apr 18;373(9672):1340. Lancet. 2010 Nov 6;376(9752):1542)","journal-title":"Lancet"},{"issue":"4","key":"646_CR33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Ustekinumab Crohn\u2019s Disease Study Group (2008) A randomized trial of Ustekinumab, a\u00a0human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology 135(4):1130\u20131141","journal-title":"Gastroenterology"},{"issue":"9","key":"646_CR34","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, \u00d8stergaard M, Wei JC, Sieper J, J\u00e4rvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ (2018) Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a\u00a0randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 77(9):1295\u20131302","journal-title":"Ann Rheum Dis"},{"issue":"9636","key":"646_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-P\u00e9rez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalh\u00e3es C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, Paediatric Rheumatology INternational Trials Organization Pediatric Rheumatology Collaborative Study Group (2008) Abatacept in children with juvenile idiopathic arthritis: a\u00a0randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383\u2013391","journal-title":"Lancet"},{"issue":"7","key":"646_CR36","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/art.40466","volume":"70","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Calvo Penad\u00e9s I, Ant\u00f3n J, \u00c1vila-Zapata F, Cuttica R, Horneff G, Foeldvari I, Keltsev V, Kingsbury DJ, Viola DO, Joos R, Lauwerys B, Gasta\u00f1aga PME, Rama ME, Wouters C, Bohnsack J, Breedt J, Fischbach M, Lutz T, Minden K, Miraval T, Ally MMTM, Rubio-P\u00e9rez N, Solau Gervais E, van Zyl R, Li X, Nys M, Wong R, Banerjee S, Lovell DJ, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) (2018) Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a\u00a0Phase III Open-Label Study. Arthritis Rheumatol 70(7):1144\u20131154","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"646_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2174\/1574886313666180508122332","volume":"13","author":"D Benfaremo","year":"2018","unstructured":"Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A (2018) Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. Curr Drug Saf 13(3):150\u2013164","journal-title":"Curr Drug Saf"},{"issue":"3","key":"646_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.semarthrit.2018.07.006","volume":"48","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R (2018) A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum 48(3):406\u2013415. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.006","journal-title":"Semin Arthritis Rheum"},{"key":"646_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/1471-2474-14-298","volume":"14","author":"Y He","year":"2013","unstructured":"He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS, Worsley AJ, Wong IC (2013) BMC Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Musculoskelet Disord 14:298. https:\/\/doi.org\/10.1186\/1471-2474-14-298","journal-title":"Musculoskelet Disord"},{"issue":"5","key":"646_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S (2016) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 74(5):841\u2013850. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"646_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","volume":"15","author":"N Ruperto","year":"2017","unstructured":"Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, Horneff G, Smolewska E, Vehe RK, Hazra A, Wang R, Mebus CA, Alvey C, Lamba M, Krishnaswami S, Stock TC, Wang M, Suehiro R, Martini A, Lovell DJ, Pediatric Rheumatology International Trials Organization (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) (2017) Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J 15(1):86. https:\/\/doi.org\/10.1186\/s12969-017-0212-y","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"646_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cpt.936","volume":"104","author":"H Kim","year":"2018","unstructured":"Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R (2018) Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther 104(2):364\u2013373","journal-title":"Clin Pharmacol Ther"},{"key":"646_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.berh.2010.02.003","volume":"24","author":"RJ Riese","year":"2010","unstructured":"Riese RJ, Krishnaswami S, Kremer J (2010) Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 24:513\u2013526","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"646_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key032","author":"AF Wells","year":"2018","unstructured":"Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, Teng L, Aelion JA (2018) Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/key032 . [Epub ahead of print]","journal-title":"Rheumatology"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0646-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-0646-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0646-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T03:59:19Z","timestamp":1721275159000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-0646-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-0646-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"assertion":[{"value":"16 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Horneff weist auf folgende Beziehungen hin: Forschungsunterst\u00fctzung: Abbvie, Chugai, MSD, Novartis, Pfizer, Roche; Honorare f\u00fcr Vortragst\u00e4tigkeit\/Advisory-Board-Teilnahme: Abbvie, Bayer, BMS, Chugai, Lilly, MSD, Novartis, Pfizer, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}